Equities Analysts Set Expectations for VRTX Q2 Earnings

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) - Stock analysts at Leerink Partnrs reduced their Q2 2025 EPS estimates for shares of Vertex Pharmaceuticals in a research note issued to investors on Wednesday, June 25th. Leerink Partnrs analyst D. Risinger now forecasts that the pharmaceutical company will post earnings of $3.59 per share for the quarter, down from their previous forecast of $3.78. Leerink Partnrs has a "Hold" rating on the stock. The consensus estimate for Vertex Pharmaceuticals' current full-year earnings is $15.63 per share. Leerink Partnrs also issued estimates for Vertex Pharmaceuticals' Q4 2025 earnings at $4.87 EPS.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing the consensus estimate of $4.29 by ($0.23). The company had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.85 billion. Vertex Pharmaceuticals had a negative net margin of 8.91% and a negative return on equity of 3.36%. Vertex Pharmaceuticals's revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period in the prior year, the business posted $4.76 EPS.

Several other equities analysts have also weighed in on VRTX. Erste Group Bank lowered shares of Vertex Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Friday, May 23rd. JPMorgan Chase & Co. lifted their price target on shares of Vertex Pharmaceuticals from $512.00 to $515.00 and gave the company an "overweight" rating in a research report on Tuesday, May 6th. Bank of America increased their price objective on Vertex Pharmaceuticals from $555.00 to $567.00 and gave the stock a "buy" rating in a research report on Monday, March 31st. Morgan Stanley reduced their target price on Vertex Pharmaceuticals from $464.00 to $460.00 and set an "equal weight" rating on the stock in a research report on Friday, June 20th. Finally, The Goldman Sachs Group reaffirmed a "buy" rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Fourteen equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Vertex Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $513.14.

Vertex Pharmaceuticals Trading Down 0.5%

Shares of VRTX stock opened at $443.40 on Friday. The company has a current ratio of 2.65, a quick ratio of 2.29 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals has a twelve month low of $377.85 and a twelve month high of $519.88. The company's 50-day moving average price is $455.45 and its 200-day moving average price is $459.02. The stock has a market cap of $113.87 billion, a price-to-earnings ratio of -113.11 and a beta of 0.41.

Institutional Investors Weigh In On Vertex Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. Activest Wealth Management acquired a new stake in Vertex Pharmaceuticals in the first quarter valued at approximately $25,000. Clal Insurance Enterprises Holdings Ltd increased its position in shares of Vertex Pharmaceuticals by 450.0% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company's stock valued at $27,000 after purchasing an additional 45 shares during the last quarter. Mascagni Wealth Management Inc. acquired a new stake in shares of Vertex Pharmaceuticals in the 4th quarter valued at $31,000. Flaharty Asset Management LLC acquired a new stake in shares of Vertex Pharmaceuticals in the 1st quarter valued at $32,000. Finally, Truvestments Capital LLC lifted its position in shares of Vertex Pharmaceuticals by 30.3% during the 4th quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company's stock worth $40,000 after purchasing an additional 23 shares during the last quarter. Institutional investors and hedge funds own 90.96% of the company's stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.